CRCT News
Three major stakeholders of the Oncopole form a strategic public-private sector alliance to boost innovation in oncology on the Toulouse campus
A multi-year framework agreement has just been signed by 3 major stakeholders present on the Oncopole campus in Toulouse: the Pierre Fabre Research Institute (IRPF), the Centre de Recherches en Cancérologie de Toulouse (CRCT-Inserm) and the Institut Universitaire du...
Hervé Avet-Loiseau among the most influential researchers in 2019
Prof. Hervé Avet-Loiseau, head of the "Myeloma Genomics" unit at IUCT-Oncopole and the "Oncogenomics and immunology of myeloma" team at CRCT is on Clarivate Analytics' list of the most influential researchers of the past decade. This is a prestigious recognition of...
IMLINFO / Cross-border Network of Personalized Immunotherapies for Non-Hodgkin’s Lymphomas
IMLINFO is a cross-border network of personalized immunotherapies for Non-Hodgkin's lymphomas (NHL) involving 7 organizations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments through the creation of a NHL...
Publication team 2 (J.S. Hoffmann) / ARTEMIS and XPF-ERCC1: 2 nucleases to prevent genetic instability
Bétous, R., Goullet de Rugy, T., Pelegrini, A.L., Queille, S., de Villartay, J.-P., & Hoffmann, J.-S.*, 2018. DNA replication stress triggers Rapid DNA Replication Fork Breakage by Artemis and XPF. PLoS Genet. 14, e1007541. DNA replication stress (DRS) leads to...
Focus: collaboration between Pierre Cordelier’s team & Neovirtech on oncolitic viruses
Discover in this France 3 TV report the collaboration between the CRCT team led by Dr. Pierre Cordelier and the Toulouse start-up Neovirtech: a therapeutic innovation opening up new perspectives in the treatment of cancer. [video width="960" height="540"...
Focus: IMMUSPHINX program – Targeting sphingolipid metabolism to improve the efficacy of immunotherapies in melanoma
Thanks to anticancer immunotherapies targeting immune checkpoints, the proportion of patients with metastatic melanoma (MM) in remission after 5 years has tripled during the last years. However, therapeutic options are sparse for patients who do not respond to...